EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer

Chiara Andolfi, Caterina Bartolini, Elisa Morales, Büşra Gündoğdu, Martin Puhr, Juan Guzman, Sven Wach, Helge Taubert, Achim Aigner iD, Iris E Eder, Florian Handle, Zoran Culig iD

Endocrinology · 27.08.2024 · 165 (10)

DOI: 10.1210/endocr/bqae114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology, online erschienen am 10.09.2024. Verfasst von Chiara Andolfi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria. Hauptthemen laut MEDLINE: Phenylthiohydantoin, Benzamides, Nitriles, Receptors, Androgen. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund FWF, German Research Foundation DFG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer progression is driven by androgen receptor (AR) activity, which is a target for therapeutic approaches. Enzalutamide is an AR inhibitor that prolongs the survival of patients with advanced prostate cancer. However, resistance mechanisms arise and impair its efficacy. One of these mechanisms is the expression of AR-V7, a constitutively active AR splice variant. The Mediator complex is a multisubunit protein that modulates gene expression on a genome-wide scale. MED12 and cyclin-dependent kinase (CDK)8, or its paralog CDK19, are components of the kinase module that regulates the proliferation of prostate cancer cells. In this study, we investigated how MED12 and CDK8/19 influence cancer-driven processes in prostate cancer cell lines, focusing on AR activity and the enzalutamide response. We inhibited MED12 expression and CDK8/19 activity in LNCaP (AR+, enzalutamide-sensitive), 22Rv1 (AR-V7+, enzalutamide-resistant), and PC3 (AR−, enzalutamide-insensitive) cells. Both MED12 and CDK8/19 inhibition reduced cell proliferation in all cell lines, and MED12 inhibition reduced proliferation in the respective 3D spheroids. MED12 knockdown significantly inhibited c-Myc protein expression and signaling pathways. In 22Rv1 cells, it consistently inhibited the AR response, prostate-specific antigen (PSA) secretion, AR target genes, and AR-V7 expression. Combined with enzalutamide, MED12 inhibition additively decreased the AR activity in both LNCaP and 22Rv1 cells. CDK8/19 inhibition significantly decreased PSA secretion in LNCaP and 22Rv1 cells and, when combined with enzalutamide, additively reduced proliferation in 22Rv1 cells. Our study revealed that MED12 and CDK8/19 regulate AR activity and that their inhibition may modulate response to enzalutamide in prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenylthiohydantoinBenzamidesNitrilesReceptors, AndrogenMediator ComplexProstatic NeoplasmsCyclin-Dependent KinasesCyclin-Dependent Kinase 8Cell ProliferationMaleHumansCell Line, TumorDrug Resistance, NeoplasmGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Mediator complexandrogen receptorenzalutamideprostate cancer

Substanzen

PhenylthiohydantoinenzalutamideBenzamidesNitrilesReceptors, AndrogenMediator ComplexCyclin-Dependent KinasesCDK19 protein, humanMED12 protein, humanCyclin-Dependent Kinase 8

Autor:innen und Institutionen

  • Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
  • University of Florence, 50 121 Florence, Italy.
  • Johannes Gutenberg University Mainz, 55122 Mainz, Germany.
  • Graudate School of Science and Engineering, Yıldız Technical University, 34220 Istanbul, Turkey.
  • Department of Urology and Pediatric Urology, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
  • Rudolf-Boehm-Institute for Pharmacology and Toxicology, Clinical Pharmacology, University of Leipzig, 04107 Leipzig, Germany.

ORCID-Profile: Achim Aigner, Zoran Culig

Förderung

  • Austrian Science Fund FWF
  • German Research Foundation DFG

Zitieren

APA

Andolfi, C., Bartolini, C., Morales, E., Gündoğdu, B., Puhr, M., Guzman, J., Wach, S., Taubert, H., Aigner, A., Eder, I. E., Handle, F., & Culig, Z. (2024). MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer. Endocrinology, 165(10). https://doi.org/10.1210/endocr/bqae114

Vancouver

Andolfi C, Bartolini C, Morales E, Gündoğdu B, Puhr M, Guzman J, et al. MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer. Endocrinology. 2024;165(10). doi:10.1210/endocr/bqae114

BibTeX
@article{Andolfi2024,
  author = {Andolfi, Chiara and Bartolini, Caterina and Morales, Elisa and Gündoğdu, Büşra and Puhr, Martin and Guzman, Juan and Wach, Sven and Taubert, Helge and Aigner, Achim and Eder, Iris E and Handle, Florian and Culig, Zoran},
  title = {MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer},
  journal = {Endocrinology},
  year = {2024},
  volume = {165},
  number = {10},
  doi = {10.1210/endocr/bqae114}
}
Kostenlos starten →